Continue to site >
Trending ETFs

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$32.92

$1.25 B

0.00%

1.29%

Vitals

YTD Return

-20.6%

1 yr return

-38.5%

3 Yr Avg Return

-3.5%

5 Yr Avg Return

9.4%

Net Assets

$1.25 B

Holdings in Top 10

43.0%

52 WEEK LOW AND HIGH

$33.3
$23.73
$52.01

Expenses

OPERATING FEES

Expense Ratio 1.29%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 62.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$100,000

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund

Investment Style

Health


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$32.92

$1.25 B

0.00%

1.29%

ETIHX - Profile

Distributions

  • YTD Total Return -20.6%
  • 3 Yr Annualized Total Return -3.5%
  • 5 Yr Annualized Total Return 9.4%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -1.28%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Eventide Healthcare & Life Sciences Fund
  • Fund Family Name
    Eventide Funds
  • Inception Date
    Dec 27, 2012
  • Shares Outstanding
    N/A
  • Share Class
    Inst
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Finny Kuruvilla

Fund Description

Under normal market conditions, the fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.


ETIHX - Performance

Return Ranking - Trailing

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
YTD -20.6% -29.0% 25.3% 92.15%
1 Yr -38.5% -60.2% 11.7% 93.64%
3 Yr -3.5%* -10.0% 19.7% 95.30%
5 Yr 9.4%* -6.4% 16.9% 56.64%
10 Yr N/A* 6.4% 18.5% N/A

* Annualized

Return Ranking - Calendar

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
2021 -25.2% -79.9% 24.2% 93.06%
2020 32.5% -13.6% 178.2% 11.11%
2019 55.4% 3.8% 63.8% 1.38%
2018 -6.9% -49.7% 21.5% 45.99%
2017 43.9% -59.8% 54.4% 2.96%

Total Return Ranking - Trailing

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
YTD -20.6% -46.5% 25.3% 83.77%
1 Yr -38.5% -60.2% 28.3% 94.27%
3 Yr -3.5%* -13.2% 20.0% 94.51%
5 Yr 9.4%* -6.4% 16.9% 55.70%
10 Yr N/A* 6.4% 18.5% N/A

* Annualized

Total Return Ranking - Calendar

Period ETIHX Return Category Return Low Category Return High Rank in Category (%)
2021 -25.2% -79.9% 24.2% 93.06%
2020 32.5% -13.6% 178.2% 11.11%
2019 55.4% 3.8% 63.8% 1.38%
2018 -6.9% -49.7% 22.2% 52.55%
2017 45.8% -59.8% 54.4% 2.22%

NAV & Total Return History


ETIHX - Holdings

Concentration Analysis

ETIHX Category Low Category High ETIHX % Rank
Net Assets 1.25 B 732 K 46.2 B 37.37%
Number of Holdings 71 21 473 47.62%
Net Assets in Top 10 683 M 2.18 K 21.6 B 26.19%
Weighting of Top 10 42.97% 12.3% 80.8% 57.62%

Top 10 Holdings

  1. Prometheus Biosciences Inc 7.68%
  2. Karuna Therapeutics Inc 5.97%
  3. Biohaven Pharmaceutical Holding Co Ltd 5.59%
  4. MyoKardia Inc 4.95%
  5. Zymeworks Inc Registered Shs When Issued 4.89%
  6. argenx SE ADR 4.56%
  7. Ascendis Pharma A/S ADR 4.24%
  8. Trillium Therapeutics Inc 4.15%
  9. Sarepta Therapeutics Inc 3.87%
  10. Us Bank Mmda - Usbgfs5 3.58%

Asset Allocation

Weighting Return Low Return High ETIHX % Rank
Stocks
85.37% 85.37% 106.13% 99.05%
Preferred Stocks
7.23% 0.00% 7.86% 1.90%
Cash
5.73% -0.10% 9.01% 5.71%
Other
1.65% -22.99% 3.38% 9.05%
Convertible Bonds
0.00% 0.00% 0.37% 25.71%
Bonds
0.00% 0.00% 12.39% 22.38%

Stock Sector Breakdown

Weighting Return Low Return High ETIHX % Rank
Healthcare
100.00% 59.26% 100.00% 10.48%
Utilities
0.00% 0.00% 0.00% 20.00%
Technology
0.00% 0.00% 22.69% 25.71%
Real Estate
0.00% 0.00% 7.13% 24.76%
Industrials
0.00% 0.00% 7.02% 25.71%
Financial Services
0.00% 0.00% 1.85% 38.10%
Energy
0.00% 0.00% 0.00% 20.00%
Communication Services
0.00% 0.00% 9.11% 23.33%
Consumer Defense
0.00% 0.00% 25.73% 29.05%
Consumer Cyclical
0.00% 0.00% 14.20% 24.29%
Basic Materials
0.00% 0.00% 14.83% 42.86%

Stock Geographic Breakdown

Weighting Return Low Return High ETIHX % Rank
US
72.16% 53.67% 104.41% 87.62%
Non US
13.21% 0.00% 45.40% 44.29%

ETIHX - Expenses

Operational Fees

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.29% 0.08% 3.13% 24.41%
Management Fee 1.10% 0.00% 1.25% 94.21%
12b-1 Fee 0.00% 0.00% 1.00% 9.09%
Administrative Fee N/A 0.03% 0.25% 22.45%

Sales Fees

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% 62.50%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

ETIHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 62.00% 0.00% 238.00% 78.95%

ETIHX - Distributions

Dividend Yield Analysis

ETIHX Category Low Category High ETIHX % Rank
Dividend Yield 0.00% 0.00% 3.95% 29.77%

Dividend Distribution Analysis

ETIHX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

ETIHX Category Low Category High ETIHX % Rank
Net Income Ratio -1.28% -2.54% 1.92% 93.71%

Capital Gain Distribution Analysis

ETIHX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

ETIHX - Fund Manager Analysis

Managers

Finny Kuruvilla


Start Date

Tenure

Tenure Rank

Dec 27, 2012

9.43

9.4%

Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.54 2.12